List view / Grid view
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
Save time by measuring 48 immune factors, generating more than 1,800 data points from a single plate, with a small sample volume.
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.
Professor Christian Heinis explains how peptides could offer the next generation of therapeutics and what is required to screen libraries of cyclic peptides.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
A picodroplet-based microfluidic method for automating the complete genome-editing workflow. Learn more in this free application note.
Sheraz Gul explores how machine learning and artificial intelligence represent an exciting opportunity for the drug discovery industry, with the potential to develop highly optimised small molecules.
